Partial Deficiency of Sphingosine-1-Phosphate Lyase Confers Protection in Experimental Autoimmune Encephalomyelitis

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Billich, Andreas ^a   Baumruker, Thomas ^a   Beerli, Christian ^a   Bigaud, Marc ^a   Bruns, Christian ^a   Calzascia, Thomas ^a   Isken, Andrea ^a   Kinzel, Bernd ^a   Loetscher, Erika ^a   Metzler, Barbara ^a   Mueller, Matthias ^a   Nuesslein Hildesheim, Barbara ^a   Kleylein Sohn, Bernadette ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENZYME; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE LYASE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEFICIENCY; ENZYME INHIBITION; GENE DELETION; LIPID BRAIN LEVEL; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPHINGOSINE 1 PHOSPHATE LYASE GENE; T LYMPHOCYTE ACTIVATION;

ALDEHYDE-LYASES; ANIMALS; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FORKHEAD TRANSCRIPTION FACTORS; HYPERSENSITIVITY, DELAYED; IMMUNOLOGIC MEMORY; INTEGRASES; LYMPH NODES; LYMPHOCYTE COUNT; MICE; MICE, KNOCKOUT; SHEEP; SPHINGOLIPIDS; SPLEEN; SURVIVAL ANALYSIS; THYMUS GLAND;

ANIMALIA; MUS;

EID: 84875470216     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059630     Document Type: Article

References (44)

1. Hla T, (2004) Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 15: 513-520.
2. Maceyka M, Milstien S, Spiegel S, (2009) Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling. J Lipid Res 50: 272-276.
3. Pyne NJ, Pyne S, (2010) Sphingosine 1-phosphate and cancer Nat Rev Cancer. 10: 489-503.
4. Swan DJ, Kirby JA, Ali S, (2010) Vascular biology: the role of sphingosine 1-phosphate in both the resting state and inflammation. J Cell Mol Med 14: 2211-2222.
5. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S, (2009) Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 78: 743-768.
6. Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH, (2010) International Union of Basic and Clinical Pharmacology LXXVIII Lysophospholipid receptor nomenclature. Pharmacol Rev 62: 579-587.
7. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, et al. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9: 883-897.
8. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, et al. (2010) Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465: 1084-1808.
9. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, et al. (2009) Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325: 1254-1257.
10. Sabbadini RA, (2011) Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol 162: 1225-1238.
11. Pitman MR, Pitson SM, (2010) Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets 10: 354-367.
12. Youm JK, Jo H, Hong JH, Shin DM, Kwon MJ, et al. (2008) K6PC-5 a sphingosine kinase activator induces anti-aging effects in intrinsically aged skin through intracellular Ca2+ signaling. J Dermatol Sci 51: 89-102.
13. Serra M, Saba JD, (2010) Sphingosine 1-phosphate lyase a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul 50: 349-362.
14. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, et al. (2010) Pharmacology and antitumor activity of ABC294640 a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 333: 129-139.
15. Dickson MA, Carvajal RD, Merrill AH, Gonen M, Cane LM, et al. (2011) A Phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res 17: 2484-2492.
16. Bagdanoff JT, Donoviel MS, Nouraldeen A, Carlsen M, Jessop TC, et al. (2010) Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R2S3R)-1234-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R2S3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1234-tetraol (LX2932). J Med Chem 253: 8650-8662.
17. Fleischmann R, (2012) Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 24: 335-341.
18. van Veldhoven PP, Mannaerts GP, (1993) Sphingosine-phosphate lyase. Adv Lipid Res 26: 69-98.
19. Vogel P, Donoviel MS, Read R, Hansen GM, Hazlewood J, et al. (2009) Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions. PLoS One 4: e4112.
20. Schmahl J, Raymond CS, Soriano P, (2007) PDGF signaling specificity is mediated through multiple immediate early genes. NatGenet 39: 52-60.
21. Allende ML, Bektas M, Lee BG, Bonifacino E, Kang J, et al. (2011) Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking. J Biol Chem 286: 7348-7358.
22. Bektas M, Allende ML, Lee BG, Chen W, Amar MJ, et al. (2010) Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. J Biol Chem 285: 10880-10889.
23. Bandhuvula P, Honbo N, Wang GY, Jin ZQ, Fyrst H, et al. (2011) S1P lyase (SPL): a novel therapeutic target for ischemia/reperfusion injury of the heart. Am J Physiol Heart Circ Physiol 300: H1753-1761.
24. Zhao Y, Gorshkova IA, Berdyshev E, He D, Fu P, et al. (2010) Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression. Am J Respir Cell Mol Biol 45: 426-435.
25. Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, et al. (2009) Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem 52: 3941-3953.
26. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, et al. (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309: 1735-1739.
27. Yu XQ, Kramer J, Moran L, O'Neill E, Nouraldeen A, et al. (2010) Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid sphingosine 1-phosphate. Xenobiotica 40: 350-356.
28. Jaegle U, Gasser JA, Mueller M, Kinzel B, (2007) Conditional transgene expression mediated by the mouse b-actin locus. Genesis 45: 659-666.
29. Goodman WA, Cooper KD, McCormick TS, (2012) Regulation generation: the suppressive functions of human regulatory T cells. Crit Rev Immunol 32: 65-79.
30. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, et al. (2000) FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction expansion and memory. J Immunol 164: 5761-5770.
31. Feil S, Valtcheva N, Feil R, (2009) Inducible Cre mice. Methods Mol Biol 530: 343-363.
32. Bode C, Sensken SC, Peest U, Beutel G, Thol F, et al. (2010) Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J Cell Biochem 109: 1232-1243.
33. Hagen N, Van Veldhoven PP, Proia RL, Park H, Merrill AH Jr, et al. (2009) Subcellular origin of sphingosine 1-phosphate is essential for its toxic effect in lyase-deficient neurons. J Biol Chem 28: 11346-11353.
34. Cyster JG, Schwab SR, (2011) Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 30: 69-94.
35. Yagi H, Kamba R, Chiba K, Soga H, Yaguchi K, et al. (2000) Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol 30: 1435-1444.
36. Weber C, Krueger A, Münk A, Bode C, Van Veldhoven PP, et al. (2009) Discontinued postnatal thymocyte development in sphingosine 1-phosphate-lyase-deficient mice. J Immunol 183: 4292-4301.
37. Metzler B, Gfeller P, Wieczorek G, Li J, Nuesslein-Hildesheim B, et al. (2008) Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure. Int Immunol 20: 633-644.
38. Sehrawat S, Rouse BT, (2008) Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3+ regulators. J Immunol 180: 7636-7647.
39. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, et al. (2011) FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 108: 751-766.
40. Ettmayer P, Billich A, Baumruker T, Mechtcheriakova D, Schmid H, et al. (2004) Fluorescence-labeled sphingosines as substrates of sphingosine kinases 1 and 2. Bioorg Med Chem Lett 14: 1555-1558.
41. Ledermann B, Bürki K, (1991) Establishment of a germ-line competent C57BL/6 embryonic stem cell line. Exp Cell Res 197: 254-258.
42. Schwenk F, Baron U, Rajewsky K, (1995) A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 23: 5080-5081.
43. Berdyshev EV, Gorshkova IA, Garcia JG, Natarajan V, Hubbard WC, (2005) Quantitative analysis of sphingoid base-1-phosphates as bisacetylated derivatives by liquid chromatography-tandem mass spectrometry. Anal Biochem 339: 129-136.
44. Bandhuvula P, Fyrst H, Saba JD, (2007) A rapid fluorescence assay for sphingosine-1-phosphate lyase enzyme activity. J Lipid Res 48: 2769-2778.